Department of Surgery, Robley Rex Veterans Affairs Medical Center, Louisville, KY, USA.
Cornea. 2013 Jan;32(1):44-53. doi: 10.1097/ICO.0b013e318254205f.
Meibomian gland dysfunction (MGD) is a common clinical problem that is often associated with evaporative dry eye disease. Alterations of the lipids of the meibomian glands have been identified in several studies of MGD. This prospective, observational, open-label clinical trial documents the improvement in both clinical signs and symptoms of disease as well as spectroscopic characteristics of the meibomian gland lipids after therapy with topical azithromycin ophthalmic solution and oral doxycycline treatment.
Subjects with symptomatic MGD were recruited. Signs of MGD were evaluated with a slit lamp. Symptoms of MGD were measured by the response of subjects to a questionnaire. Meibum lipid-lipid interaction strength, conformation, and phase transition parameters, and meibum protein content were measured using Fourier transform infrared spectroscopy and principal component analysis. Terpenoids, short-chain CH3 moieties, lipid oxidation, wax, cholesterylesters and glycerides were measured with a proton nuclear magnetic resonance (H-NMR) spectrometer.
Topical therapy with azithromycin and oral therapy with doxycycline relieved signs and symptoms and restored the lipid properties of the meibomian gland secretion toward normal. Compared with 4 weeks of azithromycin treatment reported in our previous study, oral doxycycline treatment was slightly less effective in improving foreign body sensation and the signs of plugging and secretion. In subjects with clinical evidence of MGD, changes in ordering of the lipids and phase transition temperature were brought closer to normal with azithromycin treatment than doxycycline treatment. Treatment with doxycycline but not azithromycin restored the Fourier transform infrared spectroscopy-principal component analysis scores and relative area of the H-NMR resonance at 1.26 ppm. Both doxycycline and azithromycin treatment restored the levels of the relative areas of the H-NMR resonance at 5.2 and 7.9 ppm to normal levels. The levels of meibum protein and meibum lipid oxidation were not influenced by azithromycin or doxycycline treatment.
The mechanism of action of doxycycline may be different from that of azithromycin in therapy of MGD. It is notable that when carotenoids in meibum are low, as in MGD, the tear film is unstable and patients have the signs and symptoms of dry eyes. When carotenoids are restored with azithromycin and doxycycline treatment, tear film stability is restored and patients no longer have the signs and symptoms of dry eyes.
睑板腺功能障碍(MGD)是一种常见的临床问题,常与蒸发性干眼症相关。几项 MGD 研究已发现睑板腺脂质发生了改变。本前瞻性、观察性、开放性临床试验记录了经局部阿奇霉素眼用溶液和口服多西环素治疗后,MGD 的临床体征和症状以及睑板腺脂质的光谱特征得到改善。
招募有症状 MGD 的受试者。使用裂隙灯评估 MGD 的体征。通过受试者对问卷的反应来测量 MGD 的症状。使用傅里叶变换红外光谱和主成分分析来测量睑脂脂质-脂质相互作用强度、构象和相转变参数以及睑脂蛋白含量。使用质子磁共振(H-NMR)光谱仪测量萜烯、短链 CH3 部分、脂质氧化、蜡、胆固醇酯和甘油酯。
局部应用阿奇霉素和口服多西环素治疗可缓解体征和症状,并使睑板腺分泌物的脂质特性恢复正常。与我们之前研究中报告的 4 周阿奇霉素治疗相比,口服多西环素治疗在改善异物感和阻塞及分泌迹象方面的效果略差。在有 MGD 临床证据的受试者中,与多西环素治疗相比,阿奇霉素治疗使脂质的有序性和相变温度改变更接近正常。多西环素治疗而不是阿奇霉素治疗恢复了傅里叶变换红外光谱-主成分分析评分和 H-NMR 共振 1.26 ppm 的相对面积。多西环素和阿奇霉素治疗均使 H-NMR 共振 5.2 和 7.9 ppm 的相对面积水平恢复正常。睑脂蛋白和睑脂氧化水平不受阿奇霉素或多西环素治疗的影响。
多西环素的作用机制与阿奇霉素在 MGD 治疗中的作用机制可能不同。值得注意的是,当睑脂中的类胡萝卜素水平较低(如 MGD 中)时,泪膜不稳定,患者出现干眼症的体征和症状。当用阿奇霉素和多西环素治疗恢复类胡萝卜素时,泪膜稳定性得到恢复,患者不再出现干眼症的体征和症状。